American Well Corporation reports developments for Amwell, a SaaS-based software platform for technology-enabled healthcare used by payers and health systems. Company updates center on quarterly and annual operating results, business reviews, investor conference participation, and equity-compensation actions such as inducement-plan grants.
The Amwell platform combines software and services that support virtual care programs across the care continuum, including virtual primary care, urgent care, clinical partner programs, scheduling, provider workflows, prescribing, and treatment-guideline reference tools. News about AMWL commonly connects these platform capabilities with payer and health system relationships, partner clinical programs, and management commentary on technology-enabled care delivery.
Amwell (NYSE: AMWL) reported third-quarter 2026 revenue of $48.991 million, exceeding its prior guidance but falling from the year-earlier quarter.
Revenue was $56.286 million a year earlier. Subscription revenue totaled $23.9 million, AMG visit revenue was $23.7 million, and platform visits reached 0.8 million. Gross margin was 53%. Net loss narrowed to $10.958 million from $31.911 million a year earlier, but widened from $9.6 million in Q2. Adjusted EBITDA, a non-GAAP earnings measure, was negative $3.6 million versus negative $1.2 million in Q2.
Amwell raised its full-year revenue outlook to $204 million–$206 million and adjusted EBITDA outlook to negative $8 million–negative $7 million. It reaffirmed AMG visit guidance of 1.32 million–1.37 million. For Q4, it expects revenue of $48 million–$50 million, adjusted EBITDA of $0 million–$1 million and positive operating cash flow.
Amwell (AMWL) will report third quarter 2026 operating results after stock market trading hours on November 3, 2026.
Management will host a live conference call and webcast at 5 p.m. ET to review results and provide a general business update. The webcast will be accessible through the company's Investors website, with a replay available for approximately 90 days.
Amwell (AMWL) published a case study on Discovery Health’s funded digital mental health benefit, which reached 22,000 activations in its first year. Introduced in South Africa in late 2023, the benefit integrates SilverCloud into existing mental healthcare pathways and the member app.
Clinically significant improvement rates were 60%, 71% and 78% for members with moderate, moderately severe and severe depression at baseline, respectively. Rates for moderate and severe anxiety were 60% and 66%. Satisfaction was 90% among surveyed users. Adjusted mental-health-related in-hospital costs were 6% lower in the year after use.
The findings come from observational modelling with adjustment for measured confounding factors. They estimate effects within the eligible invited population, not direct comparisons with alternative treatments, and reflect Discovery Health’s population and implementation.
Amwell (AMWL) received a non-binding Letter of Intent from the U.S. Department of Veterans Affairs to deploy its virtual health platform across the VA enterprise.
The VA states it intends to use Amwell to help modernize its digital health infrastructure and expand connected care for more than nine million Veteran beneficiaries. The platform is expected to support a broad range of clinical services, enhance care coordination, and improve access to secure, reliable virtual care nationwide. The VA’s decision follows a comprehensive evaluation in which Amwell’s scalable video, interoperability, cybersecurity compliance, and support for integrated care delivery were key factors. Any agreement remains subject to negotiation and federal procurement requirements.
Amwell (AMWL) received Frost & Sullivan's 2026 United States Technology Innovation Leadership Recognition in the Technology-Enabled Care Platforms industry. The award highlights Amwell's unified platform that connects consumer experiences, clinician workflows, care programs, and partner solutions to reduce healthcare fragmentation.
Frost & Sullivan's 12‑month evaluation assessed Amwell across technology leverage factors such as innovation, development efficiency, and commercialization, and business impact factors including financial performance, customer acquisition, and growth potential. The Amwell Platform is described as reliable, flexible, and clinically integrated, supporting large-scale virtual care, condition management, remote monitoring, and digital therapeutics for health plans and healthcare organizations.
Amwell (AMWL) announced participation in two upcoming investor conferences in September 2026. The company will attend the Wells Fargo 21st Annual Healthcare Conference on September 9 in Boston, MA, and the Morgan Stanley 24th Annual Global Healthcare Conference on September 16 in New York, NY, which includes an in-person fireside chat from 1:05 p.m. to 1:40 p.m. ET. CFO and COO Mark Hirschhorn will represent Amwell at both events, and webcast details, where available, will be posted on the company’s investor relations website.
Amwell (NYSE: AMWL) granted restricted stock units (RSUs) covering an aggregate 6,679 shares of Class A common stock to two new non-executive employees on August 7, 2026, as a material inducement to join the company.
According to Amwell, 25% of each grant vests on the first anniversary of the grant date, with the remaining 75% vesting in substantially equal quarterly installments thereafter, and full vesting occurring on the first day of the month following the 48‑month anniversary. The awards were approved by the Compensation Committee under American Well Corporation’s 2024 Inducement Plan and rely on the employment inducement exemption in NYSE Rule 303A.08, with this press release issued to meet that rule’s public announcement requirement.
Amwell (NYSE: AMWL) reported Q2 2026 revenue of $52.0 million, at the top of its guidance range, including $25.7 million in subscription revenue and $24.4 million from Amwell Medical Group visits. Gross margin was 53%. Net loss was ($9.6) million, improving from ($10.3) million in Q1 2026, while adjusted EBITDA was ($1.2) million versus ($3.1) million in Q1. Total platform visits were 0.8 million.
For 2026, Amwell raised the low end of its revenue outlook to $200–$205 million (from $195–$205 million) and improved adjusted EBITDA guidance to ($9)–($7) million (from ($16)–($12) million), reaffirmed AMG visit guidance of 1.32–1.37 million, and reiterated its goal of positive operating cash flow in Q4 2026. The company ended June 30, 2026 with $196.7 million in cash, cash equivalents and restricted cash and reported no debt.
Amwell (NYSE: AMWL) announced it will report its second quarter 2026 operating results after market close on Tuesday, August 4. Management will host a live conference call and webcast at 5 p.m. ET to review results and provide a general business update.
The live audio webcast will be available in the Investors section of Amwell's website, with a replay accessible at investors.amwell.com for about 90 days. Amwell describes its business as offering a comprehensive SaaS-based, technology-enabled care platform used by payers and health systems to support diverse clinical programs and online care access.
Amwell (NYSE: AMWL) reported results from a large, NIMH-funded randomized trial of its SilverCloud digital behavioral health platform, published in Nature Human Behaviour. The study followed 6,205 at-risk college students over two years across 26 U.S. campuses.
Students offered SilverCloud showed 74.4% participation versus 30.2% with traditional behavioral health pathways and had 4.3% lower prevalence of any measured mental disorder at six weeks, 4.9% at six months, and 3.8% at two years. According to Amwell, this difference could correspond to about $1.18 million in avoided mental health–related costs within the study sample.